MAPLE GROVE, Minn., Sept. 14, 2021 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced its partnership with Cove, a telemedicine company focused entirely on migraine. Upsher-Smith's non-oral acute migraine medication, Tosymra®(sumatriptan nasal spray) 10 mg, will now be offered through Cove's telemedicine platform as a treatment option for patients, particularly those who may not have easy access to specialized migraine care. Tosymra® is indicated for the acute treatment of migraine with or without aura in adults.
Cove connects migraine patients with an independent, licensed healthcare provider who can manage their migraine care and help identify the best treatment option. Patients interested in learning if Tosymra® is right for them can:
Eligible commercially insured patients may pay as little as $0* for Tosymra®and receive free home delivery when their prescription is filled through Blink Pharmacy Plus, Upsher-Smith's partner pharmacy and a leading patient access solution.
"More than 80% of our patients turn to Cove because they do not have access to specialized migraine care," added Caroline Hofmann, General Manager of Cove. "Our telemedicine platform matches each patient with a doctor who focuses on migraine, who will create a personalized migraine treatment plan and work to determine which products are right for an individual's needs. We are pleased to add Tosymra® to our offering of treatment options, particularly for those who otherwise may not have been able to access this important prescription migraine medication."
Tosymra® (sumatriptan nasal spray) 10 mg is a fast and powerful, ready-to-use 10 mg sumatriptan nasal spray with mist-like administration. It is used to treat acute migraine with or without aura in adults. This non-oral, non-injectable treatment may be a good option for patients who are dissatisfied with their current acute migraine medication due to slow onset of relief or experience nausea with their migraines that makes it difficult to take oral medications.
Tosymra® can provide migraine pain relief in as little as 10 minutes for some patients with just one spray (13% vs 5% for placebo; 57% of patients had pain relief at 2 hours vs. 21% for placebo).1-3 The time to onset and degree of pain relief varies by patient.
Tosymra® is administered as a single mist-like spray in one nostril at the onset of a migraine. It is supplied in a portable, single-use device that does not require refrigeration. It is convenient and simple for patients to use.
Cove is a full-service healthcare company that offers personalized treatment solutions for migraine sufferers. Cove aims to empower migraine sufferers by providing direct access to high-quality, affordable migraine care, personalized to each customer and their specific needs. In addition to Tosymra®, Cove offers acute and preventative treatments for migraine, anti-nausea medications, and clinically-proven supplements. For more information, visit www.withcove.com.
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings generics and brands to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit www.upsher-smith.com.
IMPORTANT SAFETY INFORMATION
Tosymra® can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop Tosymra and get emergency medical help if you have any signs of heart attack:
Tosymra is not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam is done and shows no problem.
Do not use Tosymra if you have:
Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.
Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.
Tosymra may cause serious side effects including:
The most common side effects of Tosymra include: tingling, dizziness, feeling warm or hot, burning feeling, feeling of heaviness, feeling of pressure, flushing, feeling of tightness, numbness, application site (nasal) reactions, abnormal taste, and throat irritation.
Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Tosymra. For more information, ask your provider.
This is the most important information to know about Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit www.upsher-smith.com or call 1-888-650-3789.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Tosymra is a prescription medicine used to treat acute migraine headaches with or without aura in adults.
Tosymra is not used to treat other types of headaches such as hemiplegic or basilar migraines or cluster headaches.
Tosymra is not used to prevent migraines. It is not known if Tosymra is safe and effective in children under 18 years of age.
Tosymra is a registered trademark of Upsher-Smith Laboratories, LLC.
*Restrictions and quantity limits apply. Visit Tosymra.com to view complete program terms and conditions. Medicare, Medicaid, and other federal and state healthcare program patients are not eligible.
1. Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
3. Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.
SOURCE Upsher-Smith Laboratories, LLC
To read more Press Release articles, click here.